Industry Perspectives on the WHO Essential Diagnostics List

Sen, Paulami; Kohli, Mikashmi; Pai, Madhukar

doi:10.1128/jcm.01637-18

Cited by 4 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EDL has been favorably received by all key stakeholders, including industry. A recent survey of industry representatives showed that the diagnostics industry largely welcomes the WHO EDL initiative and agrees that it will help improve access to diagnostics in Low-and Middle-Income Countries (LMICs) [13]. Industry members, however, did express concerns about the use of EDL as a price capping tool, and the need for the document to be updated frequently to ensure uptake of new tools [13].…”

Section: Rationale For An Edlmentioning

confidence: 99%

Essential Diagnostics: A Key Element of Universal Health Coverage

Kohli¹

2019

DSAHMJ

Self Cite

View full text Add to dashboard Cite

Good primary care is an essential precondition for a decent healthcare system. In fact, primary health care is at the heart of Universal Health Coverage (UHC). UHC, in turn, is critical to achieve the sustainable development goals. While access to essential medicines is explicit in UHC, access to essential diagnostics has received little attention. In May 2018, the World Health Organization (WHO) published the first Essential Diagnostics List (EDL), and declared its commitment to give equal importance to diagnostic tests and essential medicines. The EDL has been positively received by a variety of stakeholders, including industry. The EDL offers countries a benchmark that they can use to measure and improve diagnostic services, and preliminary data from India show limited access to essential tests at the primary care level. Some countries, notably India, have already begun developing National EDLs (NEDLs). Hopefully, such national efforts will enable the implementation of EDLs, and improve access to diagnostics. It is time for Low-and Middle-Income Countries (LMICs) to not only increase coverage of health care, but also improve quality of care. Access to essential tests is the first key step in improving quality of care.

show abstract

Section: Rationale For An Edlmentioning

confidence: 99%

Essential Diagnostics: A Key Element of Universal Health Coverage

Kohli¹

2019

DSAHMJ

Self Cite

View full text Add to dashboard Cite

show abstract

“…It complements the WHO Essential Medicines List (EML) and links medicines with diagnostic tests to advance the UHC 11, 15 . It paves the way toward improved healthcare delivery and ultimately better patient outcomes by promoting greater equitable access to quality and affordable diagnostics at all levels of the healthcare delivery system 16 . To ensure its impact, countries will need to develop national lists that suit their national or regional needs, disease burdens, and health system capacities 2, 5, 17 .…”

Section: Introductionmentioning

confidence: 99%

Implementing essential diagnostics-learning from essential medicines: A scoping review

Nyanchoka

Mulaku

Nyagol

et al. 2022

Preprint

View full text Add to dashboard Cite

Background The World Health Organization (WHO) model list of Essential In vitro Diagnostic (EDL) introduced in 2018 complements the established Essential Medicines List (EML) and improves its impact on advancing universal health coverage and better health outcomes. We conducted a scoping review of the literature on the implementation of the WHO essential lists in Africa to inform the implementation of the recently introduced EDL. Methods We searched eight electronic databases for studies reporting on the implementation of the WHO EDL and EML in Africa. Two authors independently conducted study selection and data extraction, with disagreements resolved through discussion. We used the Supporting the Use of Research Evidence (SURE) framework to extract themes and synthesized findings using thematic content analysis. We used the Mixed Method Appraisal Tool (MMAT) version 2018 to assess the quality of included studies where applicable. Results We included 172 studies reporting on EDL and EML after screening 3,813 articles titles and abstracts and 1,545 full-text papers. Most (75%, n=129) included studies were purely quantitative in design comprising descriptive cross-sectional designs (60%, n=104), 15% (n=26) were purely qualitative, and 10% (n=17) had mixed-methods approaches. There were no qualitative or randomised experimental studies about the EDL. The main barrier facing the EML and EDL was poorly equipped health facilities - including unavailability or stock-outs of essential in vitro diagnostics and medicines and inadequate infrastructure to enable health service delivery. Financial and non-financial incentives to health facilities and workers were a key enabler to the implementation of the EML however, their impact differed from one context to another. Fifty-six (33%) of the included studies were of high quality. Conclusions The EDL implementation at the national level can learn from health system interventions to improve the availability and supply of essential medicines such as financial and non-financial incentives in different contexts.

show abstract

“…It complements the WHO Essential Medicines List (EML) and links medicines with diagnostic tests to advance the UHC [11,15]. It paves the way toward improved healthcare delivery and ultimately better patient outcomes by promoting greater equitable access to quality and affordable diagnostics at all levels of the healthcare delivery system [16]. Countries need to adopt and develop national lists that suit their national or regional needs, disease burdens, and health system capacities to ensure their impact on healthcare practice and patient outcomes [2,5,17].…”

Section: Introductionmentioning

confidence: 99%

Implementing essential diagnostics-learning from essential medicines: A scoping review

Nyanchoka

Mulaku²,

Nyagol³

et al. 2022

PLOS Glob Public Health

View full text Add to dashboard Cite

The World Health Organization (WHO) model list of Essential In vitro Diagnostic (EDL) introduced in 2018 complements the established Essential Medicines List (EML) and improves its impact on advancing universal health coverage and better health outcomes. We conducted a scoping review of the literature on implementing the WHO essential lists in Africa to inform the implementation of the recently introduced EDL. We searched eight electronic databases for studies reporting on implementing the WHO EDL and EML in Africa. Two authors independently conducted study selection and data extraction, with disagreements resolved through discussion. We used the Supporting the Use of Research Evidence (SURE) framework to extract themes and synthesised findings using thematic content analysis. We used the Mixed Method Appraisal Tool (MMAT) version 2018 to assess the quality of included studies. We included 172 studies reporting on EDL and EML after screening 3,813 articles titles and abstracts and 1,545 full-text papers. Most (75%, n = 129) studies were purely quantitative in design, comprising descriptive cross-sectional designs (60%, n = 104), 15% (n = 26) were purely qualitative, and 10% (n = 17) had mixed-methods approaches. There were no qualitative or randomised experimental studies about EDL. The main barrier facing the EML and EDL was poorly equipped health facilities—including unavailability or stock-outs of essential in vitro diagnostics and medicines. Financial and non-financial incentives to health facilities and workers were key enablers in implementing the EML; however, their impact differed from one context to another. Only fifty-six (33%) of the included studies were of high quality. Poorly equipped and stocked health facilities remain an implementation barrier to essential diagnostics and medicines. Health system interventions such as financial and non-financial incentives to improve their availability can be applied in different contexts. More implementation study designs, such as experimental and qualitative studies, are required to evaluate the effectiveness of essential lists.

show abstract

Industry Perspectives on the WHO Essential Diagnostics List

Cited by 4 publications

References 3 publications

Essential Diagnostics: A Key Element of Universal Health Coverage

Essential Diagnostics: A Key Element of Universal Health Coverage

Implementing essential diagnostics-learning from essential medicines: A scoping review

Implementing essential diagnostics-learning from essential medicines: A scoping review

Contact Info

Product

Resources

About